Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-0b227cd2a54454e66a70766913e35ba2"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-0b227cd2a54454e66a70766913e35ba2"/>
<resource>
<Composition>
<id value="composition-en-0b227cd2a54454e66a70766913e35ba2"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-0b227cd2a54454e66a70766913e35ba2"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-0b227cd2a54454e66a70766913e35ba2</b></p><a name="composition-en-0b227cd2a54454e66a70766913e35ba2"> </a><a name="hccomposition-en-0b227cd2a54454e66a70766913e35ba2"> </a><a name="composition-en-0b227cd2a54454e66a70766913e35ba2-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/02/221/003</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - pegasys</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/02/221/003"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp0b227cd2a54454e66a70766913e35ba2"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - pegasys"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Pegasys is and what it is used for</li><li>What you need to know before you use Pegasys</li><li>How to use Pegasys</li><li>Possible side effects</li><li>How to store Pegasys</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What pegasys is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What pegasys is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Pegasys contains the active substance peginterferon alfa-2a, which is a long-acting interferon. Interferon is a protein that modifies the response of the body's immune system to help fight infections and severe diseases. Pegasys is used to treat chronic hepatitis B or chronic hepatitis C in adults. It is also used to treat chronic hepatitis B in children and adolescents aged 3 years and older and chronic hepatitis C in children and adolescents aged 5 years and older, who have not been treated before. Both chronic hepatitis B and C are viral infections of the liver.</p><p>Chronic Hepatitis B: Pegasys is usually used alone. Chronic Hepatitis C: Pegasys is used in combination with other medicines, for the treatment of chronic hepatitis C (CHC).</p><p>Refer also to the package leaflets of any other medicines that are used in combination with Pegasys.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take pegasys"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take pegasys"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not use Pegasys</p><p>if you are allergic to peginterferon alfa-2a, to any interferon or any of the other ingredients of this medicine (listed in section 6).</p><p>if you have ever had a heart attack or have been hospitalised for serious chest pains in the last six months.</p><p>if you have, so called autoimmune hepatitis.</p><p>if you have advanced liver disease and your liver does not work properly (e.g. your skin has become yellow).</p><p>if the patient is a child less than 3 years old.</p><p>if the patient is a child who has ever had serious psychiatric conditions such as severe depression or thoughts of committing suicide.</p><p>if you are infected with both the hepatitis C virus and the human immunodeficiency virus, and your liver does not work properly (e.g. your skin has become yellow).</p><p>if you are being treated with telbivudine, a medicine for hepatitis B infection (see Other medicines and Pegasys ).</p><p>Warnings and precautions Talk to your doctor, or pharmacist or nurse before using Pegasys</p><p>if you have had a severe nervous or mental disorder.</p><p>if you have ever had depression or symptoms associated with depression (e.g. feelings of sadness, dejection, etc.).</p><p>if you are an adult who has or had a history of substance abuse (e.g. alcohol or drugs).</p><p>if you have psoriasis, it may get worse during treatment with Pegasys.</p><p>if you have a problem with your liver other than hepatitis B or C.</p><p>if you have diabetes or high blood pressure, your doctor may ask you to have an eye examination.</p><p>if you have been told you have VKH syndrome.</p><p>if you have thyroid disease that is not well controlled with medicines.</p><p>if you have ever had anaemia.</p><p>if you have had an organ transplant (liver or kidney) or have one planned in the near future.</p><p>if you are coinfected with HIV and treated with anti HIV medicinal products.</p><p>if you have been withdrawn from previous therapy for Hepatitis C because of anaemia or low blood count.</p><p>Once you have started Pegasys treatment, talk to your doctor, nurse or pharmacist:</p><p>if you develop symptoms associated with depression (e.g. feelings of sadness, dejection, etc.) (see section 4).</p><p>if you notice a change in your vision.</p><p>if you develop symptoms associated with a cold or other respiratory infection (such as cough, fever or any difficulty in breathing).</p><p>if you think you are getting an infection (such as pneumonia) as when receiving Pegasys you may temporarily have a greater risk of getting an infection.</p><p>if you develop any signs of bleeding or unusual bruising, check with your doctor immediately.</p><p>if you develop signs of a severe allergic reaction (such as difficulty in breathing, wheezing or hives) while on this medication, seek medical help immediately.</p><p>if you develop symptoms of Vogt-Koyanagi-Harada syndrome; combination of complaints of neck stiffness, headache, loss of colour in skin or hair, eye disorders (such as blurred vision), and/or hearing abnormality (such as ringing in the ears).</p><p>During treatment your doctor will take blood samples regularly to check for changes in your white blood cells (cells that fight infection), red blood cells (cells that carry oxygen), platelets (blood clotting cells), liver function, glucose (blood sugar levels) or changes in other laboratory values.</p><p>Dental and gum disorders, which may lead to loss of teeth, have been reported in patients receiving Pegasys and ribavirin combination therapy. In addition, dry mouth could have a damaging effect on teeth and membranes of the mouth during long-term treatment with the combination of Pegasys with ribavirin. You should brush your teeth thoroughly twice daily and have regular dental examinations. In addition, some patients may experience vomiting. If you have this reaction, be sure to rinse your mouth thoroughly afterwards.</p><p>Children and adolescents Pegasys use is restricted to children and adolescents with chronic hepatitis C aged 5 years and above or children and adolescents with chronic hepatitis B aged 3 years and above. Pegasys must not be given to children below the age of 3 years because it contains benzyl alcohol and may cause toxic reactions and allergic reactions in these children.</p><ul><li>If your child has or has ever had a psychiatric disorder, talk to your doctor, who will monitor your child for signs or symptoms of depression (see section 4).</li><li>When receiving Pegasys, your child may have slower growth and development (see section 4).</li></ul><p>Other medicines and Pegasys Do not use Pegasys if you are taking telbivudine (see Do not use Pegasys ) because the combination of these medicines increases the risk of developing peripheral neuropathy (numbness, tingling, and/or burning sensations in the arms and/or legs). Therefore, the combination of Pegasys with telbivudine is contraindicated. Tell your doctor or pharmacist if you are being treated with telbivudine. Tell your doctor if you are taking medicines for asthma, because the dose for your asthma medicine may need to be changed.</p><p>Patients who also have HIV infection: Tell your doctor if you are taking anti-HIV therapy. Lactic acidosis and worsening liver function are side effects associated with Highly Active Anti-Retroviral Therapy (HAART), an HIV treatment. If you are receiving HAART, the addition of Pegasys + ribavirin may increase your risk of lactic acidosis or liver failure. Your doctor will monitor you for signs and symptoms of these conditions. Patients receiving zidovudine in combination with ribavirin and alfa interferons are at increased risk of developing anaemia. Patients receiving azathioprin in combination with ribavirin and peginterferon are at increased risk of developing severe blood disorders. Please be sure to read the ribavirin package leaflet also.</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. When Pegasys is used in combination with ribavirin, both male and female patients must take special precautions in their sexual activity if there is any chance for pregnancy to occur, as ribavirin can be very damaging to an unborn baby:</p><ul><li>if you are a woman of childbearing potential who is taking Pegasys in combination with ribavirin, you must have a negative pregnancy test before treatment, each month during therapy and for the 4 months after treatment is stopped. You must use an effective contraceptive during the time you are taking the treatment and for 4 months after stopping treatment. This can be discussed with your doctor.</li><li>if you are a man who is taking Pegasys in combination with ribavirin, do not have sex with a pregnant woman unless you use a condom. This will lessen the chance for ribavirin to be left in the woman s body. If your female partner is not pregnant now, but is of childbearing potential, she must be tested for pregnancy each month during treatment and for the 7 months after treatment has stopped. You or your partner must use an effective contraceptive during the time you are taking the treatment and for 7 months after stopping treatment. This can be discussed with your doctor.</li></ul><p>Ask your doctor or pharmacist for advice before taking any medicine. It is not known whether this product is present in human milk. Therefore, do not breast-feed an infant if you are taking Pegasys. In combination therapy with ribavirin, take notice of the respective informing texts of ribavirin containing medicinal products.</p><p>Refer also to the package leaflets of any other medicines that are used in combination with Pegasys.</p><p>Driving and using machines Do not drive or use machines if you feel drowsy, tired, or confused while taking Pegasys.</p><p>Benzyl alcohol<br/>Pegasys contains 10 mg benzyl alcohol in each vial which is equivalent to 10 mg/ml.</p><p>Benzyl alcohol may cause toxic reactions and allergic reactions.</p><p>Benzyl alcohol has been linked with the risk of severe side effects including breathing problems (called gasping syndrome ) in young children. Pegasys must not be given to premature babies, neonates or children up to 3 years old.<br/>Ask your doctor or pharmacist for advice if you are pregnant or breast feeding, or if you have a liver or kidney disease. This is because large amounts of benzyl alcohol can build-up in your body and may cause side effects (called metabolic acidosis ).</p><p>Sodium Pegasys contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially sodium-free .</p></div>
</text>
</section>
<section>
<title value="3. How to take pegasys"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take pegasys"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Pegasys dosing Your doctor has determined the exact dose of Pegasys, and will tell you how often to use it. If necessary, the dose may be changed during treatment. Do not exceed the recommended dose.</p><p>Pegasys is used alone only if you cannot take ribavirin for any reason.</p><p>Pegasys given alone or in combination with ribavirin is usually given at a dose of 180 micrograms once a week. The duration of combination treatment varies from 4 to 18 months depending on the type of virus you are infected with, on treatment response and whether you have been treated before. Please check with your doctor and follow the recommended duration of treatment. Pegasys injection is normally taken at bedtime.</p><p>Use in children and adolescents Your doctor has determined the exact dose of Pegasys for your child and will tell you how often to use it. The usual dose of Pegasysis based on your child s height and weight. If necessary, the dose may be changed during treatment. It is recommended that Pegasys pre-filled syringes be used for children and adolescents, as they allow for dose adjustments. Do not exceed the recommended dose.</p><p>The duration of combination treatment in children with chronic hepatitis C varies from 6 to 12 months depending on the type of virus your child is infected with and their response to therapy. In chronic hepatitis B the duration of Pegasys treatment is 48 weeks. Please check with your doctor and follow the recommended duration of treatment. Pegasys injection is normally taken at bedtime.</p><p>Pegasys is intended for subcutaneous use (under the skin). This means that Pegasys is injected with a short needle into the fatty tissue under the skin in the abdomen or thigh. If you are injecting this medicine yourself, you will be instructed how to give the injection. Detailed instructions are provided at the end of this leaflet (see How to inject Pegasys ).</p><p>Use Pegasys exactly as described by your doctor, for as long as prescribed by your doctor. If you have the impression that the effect of Pegasys is too strong or too weak, talk to your doctor or pharmacist.</p><p>Combination therapy with ribavirin in chronic hepatitis C In the case of combination therapy with Pegasys and ribavirin, please follow the dosing regimen recommended by your doctor.</p><p>Combination therapy with other medicines in chronic hepatitis C In the case of combination therapy with Pegasys, please follow the dosing regimen recommended by your doctor and refer also to the package leaflets of any other medicines that are used in combination with Pegasys.</p><p>If you use more Pegasys than you should Contact your doctor or pharmacist as soon as possible.</p><p>If you forget to take Pegasys If you realise you missed your injection 1 or 2 days after it was scheduled, you should inject your recommended dose as soon as possible. Take your next injection on the regularly scheduled day. If you realise you missed your injection 3 to 5 days after it was scheduled, you should take your injection at the recommended dose as soon as possible. Take your next doses at 5 day intervals until you return to your regularly scheduled day of the week. As an example: Your regular weekly Pegasys injection is on Monday. You remember on Friday that you forgot to take your injection on Monday (4 days late). You should inject your regularly scheduled dose immediately on Friday and take your next injection on Wednesday (5 days after your Friday dose). Your next injection will be on the Monday, 5 days later after the Wednesday injection. You are now back on your regularly scheduled day and should continue your injections every Monday. If you realise you missed your injection 6 days after it was scheduled, you should wait and take your dose on the next day, your regularly scheduled day. Contact your doctor or pharmacist if you need any help determining how to manage a missed dose of Pegasys.</p><p>Do not take a double dose to make up for a forgotten dose. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Some people get depressed when taking Pegasys alone or in combination treatment with ribavirin, and in some cases people have had suicidal thoughts or aggressive behaviour (sometimes directed against others such as thoughts about threatening the life of the others). Some patients have actually committed suicide. Be sure to seek emergency care if you notice that you are becoming depressed or have suicidal thoughts or change in your behaviour. You may want to consider asking a family member or close friend to help you stay alert to signs of depression or changes in your behaviour.</p><p>Growth and development (children and adolescents): Some children and adolescents treated with Pegasys for chronic hepatitis B for 48 weeks did not grow or gain weight as much as expected for their age. It is not yet known whether they will return to their projected height and weight after completing treatment.</p><p>With up to one year of treatment with Pegasys in combination with ribavirin, some children and adolescents with chronic hepatitis C did not grow or gain weight as much as expected. While most children returned to their projected height within two years after completing treatment, and the majority of the remaining children within six years after completing treatment, it remains possible that Pegasys may affect the final adult height.</p><p>Tell your doctor immediately if you notice any of the following side effects: severe chest pain; persistent cough; irregular heartbeat; trouble breathing; confusion; depression; severe stomach pain; blood in stool (or black, tarry stools); severe nosebleed; fever or chills; problems with your eyesight. These side effects can be serious and you may need urgent medical attention.</p><p>Very common side effects with the combination of Pegasys and ribavirin (may effect more than 1 in people) are:</p><p>Metabolic disorders: Loss of appetite Psychiatric and nervous system disorders: Feeling depressed (feeling low, feeling bad about yourself or feeling hopeless), anxiety, inability to sleep, headache, difficulty concentrating and dizziness Breathing disorders: Cough, shortness of breath Digestive system disorders: Diarrhoea, nausea, abdominal pain Skin disorders: Loss of hair, and skin reactions (including itching, dermatitis and dry skin) Muscle and bone disorders: Pain in joints and muscles General disorders: Fever, weakness, tiredness, shaking, chills, pain, injection site irritation and irritability (getting easily upset)</p><p>Common side effects with the combination of Pegasys and ribavirin (may affect up to 1 in 10 people) are:</p><p>Infections: Fungal, viral and bacterial infections. Upper respiratory infection, bronchitis, fungal infection of the mouth and herpes (a common recurring viral infection affecting the lips, mouth) Blood disorders: Low platelet count (affecting the clotting ability), anaemia (low red cell count) and enlarged lymph glands Hormone system disorders: Overactive and underactive thyroid gland Psychiatric and nervous system disorders: Mood /emotion changes, aggression, nervousness, decreased sexual desire, poor memory, fainting, decreased muscle strength, migraine, numbness, tingling, burning sensation, tremor, changes in the sense of taste, nightmares, sleepiness Eye disorders: Blurry vision, eye pain, eye inflammation and dry eyes Ear disorders: ear pain Heart and blood vessel disorders: Rapid heart rate, pulsation of the heart beats, swelling in the extremities, flushing Breathing disorders: Shortness of breath with activity, nose bleeds, nose and throat inflammation, infections of the nose and sinuses (air-filled spaces found in the bones of the head and face), runny nose, sore throat Digestive system disorders: Vomiting, indigestion, difficulty swallowing, mouth ulceration, bleeding gums, inflammation of tongue and mouth, flatulence (excess amount of air or gases), dry mouth and loss of weight Skin disorders: Rash, increased sweating, psoriasis, hives, eczema, sensitivity to sunlight, night sweats Muscle and bone disorders: Back pain, joint inflammation, muscle weakness, bone pain, neck pain, muscle pain, muscle cramps Reproductive system disorders: Impotence (inability to maintain an erection) General disorders: Chest pain, flu-like illness, malaise (not feeling well), lethargy, hot flushes, thirst</p><p>Uncommon side effects with the combination of Pegasys and ribavirin (may affect up to 1 in people) are:</p><p>Infections: Lung infection, skin infections Neoplasms benign and malignant disorders: Liver tumour Immune system disorders: Sarcoidosis (areas of inflamed tissue occurring throughout the body), inflammation of the thyroid Hormone system disorders: Diabetes (high blood sugar) Metabolic disorders: Dehydration Psychiatric and nervous system disorders: Thoughts of suicide, hallucinations, peripheral neuropathy (disorder of the nerves affecting the extremities) Eye disorders: Bleeding in the retina (back of the eye) Ear disorders: Hearing loss Heart and blood vessel disorders: High blood pressure Breathing disorders: Wheezing Digestive system disorders: Gastrointestinal bleeding Liver disorders: Poor functioning of the liver Rare side effects with the combination of Pegasys and ribavirin (may affect up to 1 in 1000 people) are:</p><p>Infections: Infection of the heart, infection of the external ear Blood disorders: Severe reduction in red blood cells, white blood cells and platelets Immune system disorders: Severe allergic reaction, systemic lupus erythematosus (an illness where the body attacks its own cells), rheumatoid arthritis (an autoimmune disease) Hormone system disorders: Diabetic ketoacidosis, a complication of uncontrolled diabetes Psychiatric and nervous system disorders: Suicide, psychotic disorders (severe problems with personality and deterioration in normal social functioning), coma (a deep prolonged unconsciousness), seizures, facial palsy (weakness of the facial muscle) Eye disorders: Inflammation and swelling of the optic nerve, inflammation of the retina, ulceration of the cornea Heart and blood vessel disorders: Heart attack, heart failure, heart pain, rapid heart rhythm, rhythm disorders or inflammation of the lining of the heart and cardiac muscle, bleeding in the brain and inflammation in the vessels Breathing disorders: Interstitial pneumonia (inflammation of the lungs including fatal outcome), blood clots in the lung Digestive system disorders: Stomach ulcer, inflammation of the pancreas Liver disorders: Liver failure, bile duct inflammation, fatty liver Muscle and bone disorders: Inflammation of the muscles Kidney disorders: Kidney failure Injury or poisoning: Substance overdose</p><p>Very rare side effects with the combination of Pegasys and ribavirin (may affect up to 1 in 10,people) are:</p><p>Blood disorders: Aplastic anaemia (failure of the bone marrow to produce red blood cells, white blood cells and platelets) Immune system disorders: Idiopathic (or thrombotic) thrombocytopenic purpura (increased bruising, bleeding, decreased platelets, anaemia and extreme weakness) Eye disorders: Loss of vision Skin disorders: Toxic epidermal necrolysis/Stevens Johnson Syndrome/erythema multiforme (a spectrum of rashes with varying degrees of severity including death which may be associated with blisters in the mouth, nose, eyes and other mucosal membranes and sloughing of the affected area of the skin), angioedema (swelling in the skin and mucosa)</p><p>Side effects with unknown frequency:</p><p>Blood disorders: Pure red cell aplasia (a severe form of anaemia where red blood cell production is decreased or stopped); it can result in symptoms such as feeling very tired with no energy Immune system disorders: Vogt Koyanagi Harada disease a rare disease characterised by loss of vision, hearing and skin pigmentation; liver and kidney transplant rejections Psychiatric and nervous system disorders: Mania (episodes of exaggerated elevation of mood) and bipolar disorders (episodes of exaggerated elevation of mood alternating with sadness and hopelessness); thoughts about threatening the life of others, stroke Eye disorders: Rare form of retinal detachment with fluid in the retina Heart and blood vessel disorders: Peripheral ischaemia (insufficient blood supply to the extremities) Digestive system disorders: Ischaemic colitis (insufficient blood supply to the bowels), changes in the colour of the tongue Muscle and bone disorders: Serious muscle damage and pain Pulmonary arterial hypertension - a disease of severe narrowing of the blood vessels in the lungs resulting in high blood pressure in the blood vessels that carry blood from the heart to the lungs. This may occur in particular in patients with risk factors such as HIV infection or severe liver problems (cirrhosis). The side effect may develop at various time points during treatment, typically several months after starting treatment with Pegasys. When Pegasys is used alone in hepatitis B or C patients, some of these effects are less likely to occur.</p><p>Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store pegasys"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store pegasys"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to the last day of that month.</p><p>Store in a refrigerator (2 C - 8 C). Do not freeze. Keep the vial in the outer carton in order to protect from light.</p><p>Do not use this medicine if you notice the vial or packaging is damaged, if the solution is cloudy or if it has floating particles or if the medicine is any colour besides colourless to light yellow.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Pegasys contains</p><p>The active substance is peginterferon alfa-2a. Each vial of 1.0 ml solution contains micrograms peginterferon alfa-2a.</p><p>The other ingredients are sodium chloride, polysorbate 80, benzyl alcohol, sodium acetate, acetic acid and water for injections.</p><p>What Pegasys looks like and contents of the pack Pegasys is presented as a solution for injection in a vial (1 ml). It is available in packs containing 1 or 4 single dose vials. Not all pack-sizes may be marketed.</p><p>Marketing Authorisation Holder</p><p>pharmaand GmbH Taborstrasse 1<br/>1020 Wien Austria</p><p>Manufacturer<br/>Loba biotech GmbH Fehrgasse 7 2401 Fischamend Austria</p><p>This leaflet was last revised in</p><p>Detailed information on this medicine is available on the European Medicines Agency website: <a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a>.</p><p>How to inject Pegasys</p><p>The following instructions explain how to use Pegasys single dose vials to inject yourself or your child. Please read the instructions carefully and follow them step by step. Your doctor or his/her assistant will instruct you on how to give the injections.</p><p>Getting ready</p><p>Wash your hand carefully before handling any of the items.</p><p>Collect the necessary items before beginning: Included in the pack:</p><p>a vial of Pegasys solution for injection Not included in the pack:</p><p>a 1 ml syringe</p><p>a long needle to withdraw Pegasys from the vial</p><p>a short needle for the subcutaneous injection</p><p>a cleansing swab</p><p>small bandage or sterile gauze</p><p>an adhesive bandage</p><p>a container for the waste material</p><p>Measuring the dose of Pegasys</p><p>Remove the protective cap from the Pegasys vial (1).</p><p>Clean the rubber top of the vial with a cleansing swab. You can save the swab to clean the skin area where you will inject Pegasys.</p><p>Remove the syringe from the wrapping. Do not touch the tip of the syringe.</p><p>Take the long needle and place it firmly on to the tip of the syringe (2).</p><p>Remove the needle guard without touching the needle and keep the syringe with the needle in your hand.</p><p>Insert the needle through the rubber top of the Pegasys vial (3).</p><p>Hold the vial and syringe in one hand and turn the vial and the syringe upside down (4).</p><p>4</p><p>With the syringe pointing up, make certain that the tip of the needle is in the Pegasys solution. Your other hand will be free to move the plunger of the syringe.</p><p>Slowly pull back the plunger to withdraw a bit more than the dose prescribed by your doctor into the syringe.</p><p>Hold the syringe with the needle in the vial pointing up, remove the syringe from the long needle while keeping the needle in the vial and without touching the tip of the syringe.</p><p>Take the short needle and place it firmly on to the tip of the syringe (5).</p><p>Remove the needle guard from the syringe needle.</p><p>Check for air bubbles in the syringe. If you see any bubbles, pull the plunger slightly back. To remove air bubbles from the syringe, hold the syringe with the needle pointing up. Tap the syringe gently to bring the bubbles to the top. Push the plunger up slowly to the correct dose. Replace the needle guard and place the syringe in a horizontal position until ready for use.</p><p>Allow the solution to reach room temperature before injection or warm the syringe between your palms.</p><p>Visually inspect the solution prior to administration: do not use if it is discoloured or if particles are present. You are now ready to inject the dose.</p><p>Injecting the solution</p><p>Select the injection site in the abdomen or thigh (except your navel or waistline). Change your injection site each time.</p><p>Clean and disinfect the skin where the injection is to be made with a cleansing swab.</p><p>Wait for the area to dry.</p><p>Remove the needle guard.</p><p>With one hand, pinch a fold of loose skin. With your other hand hold the syringe as you would a pencil.</p><p>Insert the needle all the way into the pinched skin at an angle of 45 to 90 (6).</p><p>Inject the solution by gently pushing the plunger all the way down.</p><p>Pull the needle straight out of the skin.</p><p>Press the injection site with a small bandage or sterile gauze if necessary for several seconds.</p><p>Do not massage the injection site. If there is bleeding, cover with an adhesive bandage.</p><p>Disposal of the injection materials</p><p>The syringe, needle and all injection materials are intended for single use and must be discarded after the injection. Dispose of the syringe and needle safely in a closed container. Ask your doctor, hospital or pharmacist for an appropriate container.</p><p>Package leaflet: Information for the user</p><p>Pegasys 90 micrograms solution for injection in pre-filled syringe Pegasys 135 micrograms solution for injection in pre-filled syringe Pegasys 180 micrograms solution for injection in pre-filled syringe peginterferon alfa-2a</p><p>Read all of this leaflet carefully before you start using this medicine because it contains important information for you.</p><p>Keep this leaflet. You may need to read it again.</p><p>If you have any further questions, ask your doctor, pharmacist or nurse.</p><p>This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp0b227cd2a54454e66a70766913e35ba2"/>
<resource>
<MedicinalProductDefinition>
<id value="mp0b227cd2a54454e66a70766913e35ba2"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp0b227cd2a54454e66a70766913e35ba2"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp0b227cd2a54454e66a70766913e35ba2</b></p><a name="mp0b227cd2a54454e66a70766913e35ba2"> </a><a name="hcmp0b227cd2a54454e66a70766913e35ba2"> </a><a name="mp0b227cd2a54454e66a70766913e35ba2-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/02/221/003</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Pegasys 180 micrograms solution for injection</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/02/221/003"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Pegasys 180 micrograms solution for injection"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
